<DOC>
	<DOCNO>NCT02935634</DOCNO>
	<brief_summary>The purpose study determine whether Nivolumab combination therapy effective Nivolumab combination Ipilimumab treat patients/subjects advance gastric cancer .</brief_summary>
	<brief_title>A Study Test Combination Treatments Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Advanced Gastric Cancer Must full activity , limited , must able walk carry light activity light house work office work Must least 1 lesion measurable disease Patients/subjects HER2 positive tumor treat trastuzumab prior enrollment Must suspect known central nervous system metastases unless adequately treat Patients/subjects autoimmune disease Patients/subjects need daily oxygen therapy Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>